Weeks 13-24: Optimization Phase By month four, most users reach stable dosing with adapted tolerability
They may be a better fit for: Individuals who do not meet bariatric surgery criteria People who prefer to avoid surgery and surgical recovery Patients looking for a more flexible or adjustable approach Individuals comfortable with long-term medication use and weekly injections People seeking gradual weight loss with fewer immediate lifestyle disruptions Many users appreciate that GLP-1 medications can typically be adjusted, paused, or discontinued under medical supervision depending on personal progress and goals
The DTR-QoL is a Japanese-specific measure of HRQoL that has been extensively employed in studies of glucose-lowering medication, including several involving GLP-1RAs [33,34,35], dipeptidyl peptidase-4 inhibitors [36,37,38], and the SGLT2i ipragliflozin [39]
The full therapeutic effect may take 16-20 weeks to manifest, particularly with the Wegovy titration schedule
Draw halfway between the 7 and 8 unit marks
Less common risks may include: Infection Hypersensitivity reactions Patients should follow post-treatment guidelines provided by their clinician to support recovery and minimize complications
